Recent results from BristolMyersSquibb support an improving outlook. The company is benefiting from strong demand for its new medications. The stock looks attractive, trading at just 7 times ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
PRINCETON, N.J., September 27, 2024--U.S. FDA Approves BristolMyersSquibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Business Wire • 6 hours ...
Results that may be inaccessible to you are currently showing.